ALT02 (trastuzumab biosimilar) / Alteogen, Qilu Pharma, Cristalia 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   6 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALT02 (trastuzumab biosimilar) / Alteogen, Qilu Pharma, Cristalia
NCT05629949: A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Completed
3
474
RoW
QL1701, Herceptin®, Docetaxel
Qilu Pharmaceutical Co., Ltd.
Breast Cancer
12/22
04/23

Download Options